Status:
UNKNOWN
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Lead Sponsor:
Technical University of Munich
Conditions:
Bladder Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumo...
Eligibility Criteria
Inclusion
- Histologically confirmed muscle-invasive urothelial carcinoma
- Age \> 18 years
- Hemoglobin \> 10g/dl
- Signed Informed Consent
- Karnofsky index \< 70%
Exclusion
- Clinically relevant second malignancy
- Severe comorbidities (e.g. NYHA III, end-stage renal disease)
- Chronic infectious disease (HIV, Tuberculosis)
- Immunosupression
- Severe psychiatric diseases
- Blood donation in the last 4 weeks
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01198808
Start Date
August 1 2010
Last Update
January 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urologische Klinik der Technischen Universität München
Munich, Bavaria, Germany, 81675